Docosahexaenoic acid

Phase 2Small molecule

MMicelle BioPharma Inc

Docosahexaenoic acid is one of 228 small molecule programs targeting Cognitive impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

227

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Retinitis PigmentosaActive, not recruiting

ConcussionActive, not recruiting

HypertensionActive, not recruiting

PeriodontitisActive, not recruiting

Breast CancerActive, not recruiting

Cystic FibrosisActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

AmblyopiaActive, not recruiting

Cognitive ImpairmentPhase 1/Phase 2

Active, not recruiting

Retinitis PigmentosaPreclinical

Active, not recruiting

ConcussionPhase 1

Active, not recruiting

HypertensionPreclinical

Active, not recruiting

PeriodontitisPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

AmblyopiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Docosahexaenoic acid

MMicelle BioPharma Inc

Phase 2

1 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Prolia

Amgen

Preclinical

14 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—7

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Periodontitis1 trial

The Effects of DHA on Periodontitis

Completed·—·Phase 2·NCT01976806·55 enrolled

Sickle Cell Disease1 trial

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Unknown status·MMicelle BioPharma Inc·Phase 2·NCT02973360·68 enrolled

Concussion1 trial

DHA For The Treatment of Pediatric Concussion Related to Sports Injury

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT01903525·40 enrolled

Cognitive impairment1 trial

Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients

Unknown status·FFudan University·Phase 1/2·NCT04242004·88 enrolled

Hypertension1 trial

Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health

Withdrawn·—·N/A·NCT02137408

7 more indications

Treatment1 trial

Evaluation of DHA for the Treatment of PSC

Completed·—·Phase 1·NCT00325013·10 enrolled

Cardiovascular1 trial

Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress

Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 1·NCT00014027·97 enrolled

Parkinson's Disease1 trial

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

Completed·VVA Office of Research and Development·Phase 1·NCT01563913·33 enrolled

Amblyopia1 trial

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

Withdrawn·JJohns Hopkins University·Phase 1/2·NCT03402789

Breast Cancer1 trial

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01849250·65 enrolled

Cystic Fibrosis1 trial

Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)

Completed·HHospices Civils de Lyon·Phase 2·NCT02690857·10 enrolled

Retinitis Pigmentosa1 trial

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

Completed·RRetina Foundation of the Southwest·N/A·NCT00004827·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Docosahexaenoic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docosahexaenoic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docosahexaenoic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Micelle BioPharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMicelle BioPharma Inc

Docosahexaenoic acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Periodontitis1 trial

Sickle Cell Disease1 trial

Concussion1 trial

Cognitive impairment1 trial

Hypertension1 trial

Treatment1 trial

Cardiovascular1 trial

Parkinson's Disease1 trial

Amblyopia1 trial

Breast Cancer1 trial

Cystic Fibrosis1 trial

Retinitis Pigmentosa1 trial

References

Drug Info

Quick Facts

Related News